David Scholten

3.6k total citations · 3 hit papers
24 papers, 2.8k citations indexed

About

David Scholten is a scholar working on Hepatology, Epidemiology and Surgery. According to data from OpenAlex, David Scholten has authored 24 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Hepatology, 18 papers in Epidemiology and 5 papers in Surgery. Recurrent topics in David Scholten's work include Liver physiology and pathology (18 papers), Liver Disease Diagnosis and Treatment (17 papers) and Liver Diseases and Immunity (6 papers). David Scholten is often cited by papers focused on Liver physiology and pathology (18 papers), Liver Disease Diagnosis and Treatment (17 papers) and Liver Diseases and Immunity (6 papers). David Scholten collaborates with scholars based in Germany, United States and South Korea. David Scholten's co-authors include David A. Brenner, Tatiana Kisseleva, Ralf Weiskirchen, Keiko Iwaisako, Christian Liedtke, Jonel Trebicka, Min Cong, Yong‐Han Paik, Christian Trautwein and Christoph H. Österreicher and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Gastroenterology and PLoS ONE.

In The Last Decade

David Scholten

23 papers receiving 2.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis

2012 615 citations Tatiana Kisseleva, Min Cong et al. Proceedings of the National Academy of Sciences profile →
Interleukin-17 Signaling in Inflammatory, Kupffer Cells, and Hepatic Stellate Cells Exacerbates Liver Fibrosis in Mice

2012 561 citations Fanli Meng, Kai Wang et al. Gastroenterology profile →
The carbon tetrachloride model in mice

2015 281 citations David Scholten, Jonel Trebicka et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David Scholten Germany	16	1.5k	1.4k	608	507	444	24	2.8k
Bernhard Saile Germany	29	1.7k 1.1×	1.2k 0.9×	725 1.2×	671 1.3×	255 0.6×	57	2.7k
Antonella Pellicoro United Kingdom	14	1.7k 1.2×	1.4k 1.0×	891 1.5×	822 1.6×	721 1.6×	21	3.6k
Peter Huebener Germany	14	916 0.6×	876 0.6×	761 1.3×	555 1.1×	538 1.2×	24	2.7k
Oliver Krenkel Germany	14	1.0k 0.7×	1.3k 0.9×	625 1.0×	367 0.7×	879 2.0×	24	2.7k
Thomas Knittel Germany	33	2.0k 1.3×	1.3k 1.0×	1.0k 1.7×	792 1.6×	354 0.8×	61	3.2k
Cecilia Grappone Italy	23	1.4k 0.9×	973 0.7×	623 1.0×	698 1.4×	247 0.6×	38	2.7k
Prakash Ramachandran United Kingdom	22	2.1k 1.4×	1.8k 1.3×	1.1k 1.8×	880 1.7×	1.1k 2.4×	41	4.3k
Mette Juul Nielsen Denmark	28	1.2k 0.8×	1.4k 1.0×	514 0.8×	465 0.9×	211 0.5×	60	2.7k
Marie‐Luise Berres Germany	26	1.0k 0.7×	1.0k 0.7×	358 0.6×	337 0.7×	524 1.2×	59	2.1k
Johannes Herkel Germany	32	1.9k 1.3×	1.6k 1.1×	503 0.8×	566 1.1×	1.2k 2.6×	73	3.5k

Countries citing papers authored by David Scholten

Since Specialization

Citations

This map shows the geographic impact of David Scholten's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Scholten with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Scholten more than expected).

Fields of papers citing papers by David Scholten

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Scholten. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Scholten. The network helps show where David Scholten may publish in the future.

Co-authorship network of co-authors of David Scholten

This figure shows the co-authorship network connecting the top 25 collaborators of David Scholten. A scholar is included among the top collaborators of David Scholten based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Scholten. David Scholten is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Meurer, Steffen K., Hacer Sahin, Ute Schaeper, et al.. (2017). Endoglin in human liver disease and murine models of liver fibrosis—A protective factor against liver fibrosis. Liver International. 38(5). 858–867. 25 indexed citations

Scholten, David, Igor Spivak, Jessica Voss, et al.. (2017). Multi-center study of liver disease in alpha1-antitrypsin deficiency: non-invasive evaluation of liver fibrosis in homozygous PiZZ patients. Journal of Hepatology. 66(1). S176–S177. 1 indexed citations

Xu, Jun, et al.. (2015). Contribution of bone marrow-derived fibrocytes to liver fibrosis.. PubMed. 4(1). 34–47. 31 indexed citations

Meurer, Steffen K., Hacer Sahin, Hermann E. Wasmuth, et al.. (2013). Overexpression of Endoglin Modulates TGF-β1-Signalling Pathways in a Novel Immortalized Mouse Hepatic Stellate Cell Line. PLoS ONE. 8(2). e56116–e56116. 42 indexed citations

Heinrichs, Daniel, Marie‐Luise Berres, Andreas Nellen, et al.. (2013). The Chemokine CCL3 Promotes Experimental Liver Fibrosis in Mice. PLoS ONE. 8(6). e66106–e66106. 57 indexed citations

Roderburg, Christoph, Mark Luedde, David Vargas Cardenas, et al.. (2013). Circulating MicroRNA-150 Serum Levels Predict Survival in Patients with Critical Illness and Sepsis. PLoS ONE. 8(1). e54612–e54612. 137 indexed citations

Liedtke, Christian, Tom Luedde, Tilman Sauerbruch, et al.. (2013). Experimental liver fibrosis research: update on animal models, legal issues and translational aspects. PubMed. 6(1). 19–19. 270 indexed citations

Kisseleva, Tatiana, Min Cong, Yong‐Han Paik, et al.. (2012). Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis. Proceedings of the National Academy of Sciences. 109(24). 9448–9453. 615 indexed citations breakdown →

Meng, Fanli, Kai Wang, Tomonori Aoyama, et al.. (2012). Interleukin-17 Signaling in Inflammatory, Kupffer Cells, and Hepatic Stellate Cells Exacerbates Liver Fibrosis in Mice. Gastroenterology. 143(3). 765–776.e3. 561 indexed citations breakdown →

10.

Sahin, Hacer, Erawan Borkham‐Kamphorst, Christoph Kuppe, et al.. (2012). Chemokine Cxcl9 attenuates liver fibrosis-associated angiogenesis in mice. Hepatology. 55(5). 1610–1619. 112 indexed citations

11.

Brenner, David A., Tatiana Kisseleva, David Scholten, et al.. (2012). Origin of myofibroblasts in liver fibrosis. PubMed. 5(S1). S17–S17. 98 indexed citations

12.

Iwaisako, Keiko, Chunyan Jiang, David Scholten, et al.. (2011). The Origin of Myofibroblasts Contributing to Liver Fibrosis in Mice. Gastroenterology. 140(5). S–917. 1 indexed citations

13.

Scholten, David, Donna Reichart, Yong Han Paik, et al.. (2011). Migration of Fibrocytes in Fibrogenic Liver Injury. American Journal Of Pathology. 179(1). 189–198. 89 indexed citations

14.

Scholten, David, Christoph H. Österreicher, Keiko Iwaisako, et al.. (2010). Genetic Labeling Does Not Detect Epithelial-to-Mesenchymal Transition of Cholangiocytes in Liver Fibrosis in Mice. Gastroenterology. 139(3). 987–998. 179 indexed citations

15.

Scholten, David, et al.. (2010). 981 EPITHELIAL-TO-MESENCHYMAL TRANSITION (EMT) IN CHOLANGIOCYTES DOES NOT CONTRIBUTE TO THE POPULATION OF α-SMA+ MYOFIBROBLASTS IN EXPERIMENTAL MODELS OF LIVER FIBROSIS. Journal of Hepatology. 52. S379–S379. 2 indexed citations

16.

Wasmuth, Hermann E., Frank Lammert, Mirko Moreno Zaldivar, et al.. (2009). Antifibrotic Effects of CXCL9 and Its Receptor CXCR3 in Livers of Mice and Humans. Gastroenterology. 137(1). 309–319.e3. 130 indexed citations

17.

Schnabl, Bernd, David Scholten, & David A. Brenner. (2008). What is the potential role of antifibrotic agents for the treatment of liver disease?. Nature Clinical Practice Gastroenterology & Hepatology. 5(9). 496–497. 13 indexed citations

18.

Wasmuth, Hermann E., Mirko Moreno Zaldivar, Marie‐Luise Berres, et al.. (2007). The fractalkine receptor CX3CR1 is involved in liver fibrosis due to chronic hepatitis C infection. Journal of Hepatology. 48(2). 208–215. 62 indexed citations

19.

Tischendorf, Jens J. W., Eray Yagmur, David Scholten, et al.. (2007). The interleukin‐6 (IL6)–174 G/C promoter genotype is associated with the presence of septic shock and the ex vivo secretion of IL6. International Journal of Immunogenetics. 34(6). 413–418. 33 indexed citations

20.

Yagmur, Eray, David Scholten, Ramin Schirin-Sokhan, et al.. (2006). Erhöhte Konzentrationen von fäkalem Calprotectin bei Patienten mit Leberzirrhose. DMW - Deutsche Medizinische Wochenschrift. 131(36). 1930–1934. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact